Know2eat

Lactobacillus rhamnosus GG

Lacticaseibacillus rhamnosus GG (ATCC 53103)

Probiotics & Gut

What lactobacillus rhamnosus gg may help with

Ranked by how strong the human evidence is — best supported first.

Best supportedDigestive comfortStrong evidence· 2 sources

Then, in order

About Lactobacillus rhamnosus GG

The single most-studied probiotic strain, isolated from a human intestinal sample in 1983 and deposited as ATCC 53103. It tolerates gastric acid and bile and adheres to intestinal mucus, which is why it was selected in the first place.

LGG is where the strain-specificity rule is easiest to see working. It has good evidence for one thing — reducing the incidence of antibiotic-associated diarrhoea, where meta-analyses put the number needed to be given the strain for one to benefit at around ten — and a much more mixed record everywhere else. The most instructive result is negative: two large, well-conducted randomised trials published together in 2018 tested LGG in children with acute gastroenteritis in emergency departments and found no benefit whatsoever, overturning a widely accepted paediatric use. That is what a strong trial does to a plausible claim, and it happened to one of the best-selling probiotics in the world.

Sold as
Capsule, Sachet, Chewable tablet, Fermented dairy drink, Drops
Standardised to
CFU per dose of the named strain ATCC 53103 — a product without this marker may not resemble what was studied.
Also known as
LGG, L. rhamnosus GG, Lactobacillus GG

Regulation: Sold as a dietary supplement in the US and as a food supplement in the EU, with no pre-market efficacy review. EFSA has rejected general probiotic health claims, so European labels cannot state a specific benefit. Product labels should name the strain designation, not just the species — a product listing only "Lactobacillus rhamnosus" is not necessarily this organism.

What the research used

The amounts, forms and durations published trials of Lactobacillus rhamnosus GG actually administered.

These are the amounts published trials administered — not a recommendation, and not a dose to copy. Trial participants were screened, supervised and given a characterised preparation. What is in a retail bottle is frequently not what was studied, and the amount that suits one person is not general advice.

  • Studied for Antibiotic-associated diarrhoea

    10–20 billion CFU

    Strong

    Capsule or sachet, daily during and shortly after the antibiotic course · Length of the antibiotic course plus about a week

    Trials typically used 1×10^10 CFU/day or more. Meta-analyses find a reduction in incidence, with roughly ten people needing to receive it for one to benefit; the effect is specific to this strain and this indication.

  • Studied for Acute infectious gastroenteritis in children

    10 billion CFU

    Strong

    Twice daily · 5 days

    Recorded because two large 2018 trials used it and found no effect on duration or severity. This dose is documented as tested and negative, not as effective.

This is general information about food, not medical advice. It cannot diagnose, treat or replace guidance from a clinician who knows your history.

When it was taken

Each window says whether a trial compared it against an alternative, or whether it is convention and pharmacology. Most timing advice is the second kind.

1 of 2 timings below were actually compared in a trial. The rest reflect convention or pharmacology.

  • With food

    Limited

    Survival through the stomach is better when a probiotic is taken with or just before a meal containing some fat, and this has been measured in vitro and in a small number of human studies. LGG is comparatively acid-tolerant, so the effect is smaller for this strain than for many others.

    Timing was tested. A trial compared this window against another and reported a difference.

  • Split through the day

    Not enough

    When used alongside antibiotics, trials generally separated the probiotic from the antibiotic dose by two hours or more. That is a sensible precaution rather than a tested variable.

    Timing was not directly compared. This reflects convention or how the compound behaves in the body, not a trial showing this window works better.

The evidence in depth

Best supported: Strong

What each association actually rests on, and the papers behind it. A rating describes the state of the research, not how promising the supplement sounds. How we rate evidence.

Digestive comfort

Gut & Digestive Health
Strong evidence

Multiple systematic reviews and meta-analyses find that Lactobacillus rhamnosus GG reduces the incidence of antibiotic-associated diarrhoea in children and adults, with roughly ten people needing to receive it for one to benefit. This is one of the few probiotic claims where consistent review-level evidence exists for a named strain and a defined indication.

What may be going on: Proposed routes include competitive exclusion of pathogens, production of antimicrobial peptides and support of tight-junction integrity, none of which has been demonstrated as the operative mechanism in people.

Strong evidence. Consistent findings across multiple good-quality human studies.

View the 2 sources

Deep research mode adds each paper’s own conclusion and stated limitations.

Bowel regularity

Gut & Digestive Health
Limited evidence

Two large randomised trials in children with acute gastroenteritis found no reduction in diarrhoea duration or severity with LGG, contradicting earlier smaller studies and meta-analyses. Where the outcome is acute infectious diarrhoea rather than antibiotic-associated diarrhoea, the best evidence is negative.

Limited evidence. Early human work, or mostly lab and animal research.

View the 3 sources

Deep research mode adds each paper’s own conclusion and stated limitations.

Immune function

Immune Health
Limited evidence

Trials in daycare and hospital settings report modest reductions in respiratory infection days with LGG, alongside trials that found nothing. The evidence is weaker and less consistent than for the gastrointestinal indications, and the effect sizes are small.

Limited evidence. Early human work, or mostly lab and animal research.

View the 3 sources

Deep research mode adds each paper’s own conclusion and stated limitations.

Skin structure and hydration

Skin Health
Not enough evidence

Trials of LGG for preventing atopic dermatitis in infants have produced conflicting results, with a well-conducted Australian trial finding no benefit and a possible increase in wheeze. There is not enough consistent evidence to support the eczema use.

Not enough evidence. Not enough human research to say anything useful yet.

View the 2 sources

Deep research mode adds each paper’s own conclusion and stated limitations.

Things to know

Interactions, contraindications and dose limits, most serious first. Concentrated extracts interact with medication in ways the whole plant does not, so this section carries more weight here than it does on a food page.

  • Avoid

    Immunocompromise, central lines and critical illness

    Live organisms can cause infection in people who cannot contain them. Cases of Lactobacillus bacteraemia and endocarditis attributed to LGG have been published, including in patients with central venous catheters, short bowel syndrome and severe immunosuppression. Probiotics should not be given to critically ill, severely immunocompromised or central-line patients without specialist advice, and this is not a theoretical precaution.

  • Worth knowing

    Evidence does not transfer between strains or indications

    Buying "a probiotic" because LGG worked in a trial is a category error. Results belong to ATCC 53103 at a stated dose for a stated indication; a different strain of the same species is a different organism, and the same strain for a different problem is untested.

  • Worth knowing

    Viability and labelling

    CFU counts are stated as of manufacture in some products and as of expiry in others, which are very different promises. Independent testing has repeatedly found products containing fewer viable organisms than labelled, or organisms not listed on the label at all.

  • Too much

    Bloating and gas in the first days

    Transient wind, bloating and changed stool consistency are common when starting and usually settle within a week.

In the food catalogue

The whole-food form, where one exists. The evidence for a concentrated extract rarely transfers to the food, or the other way round — these are cross-links, not equivalents.

Plain yogurtA fermented food supplying live cultures, though usually different…

Evidence ratings on this page: 1 strong evidence, 2 limited evidence, 1 not enough evidence.

Supplements are sold in the US without pre-market review of efficacy or safety. Nothing on this page is a recommendation to take Lactobacillus rhamnosus GG, or a dose to follow.